RNA Approach to Rare Cardiomyopathies
Date: August 19, 2026
Time: 6:00pm EDT
Join Atrium Therapeutics for an introduction to the company and its mission to pioneer targeted RNA delivery directly to the heart, transforming care for people living with rare, life-threatening genetic cardiomyopathies.
Hear how Atrium’s lead programs — ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy — are designed to address the underlying genetic drivers of these conditions for the first time.
Leading genetic cardiomyopathy RNA researchers will share how RNA therapies can help cardiomyopathy patients. RNA therapies use ribonucleic acid molecules to prevent or treat diseases directly by influencing genetic messaging.
Presenters:
Dr. Husam Younis, the Chief Scientific Officer at Atrium Therapeutics, with more than 20 years of experience in drug discovery and development, including in rare disease.
Quan M. Bui, MD Assistant Professor of Medicine Advanced Heart Failure/Transplant Cardiology Division of Cardiovascular Medicine University of California, San Diego
Register NowLMNA Gene Therapy: A New Approach to LMNA Cardiomyopathy
Date: September 9, 2026
Time: 6:00pm EDT
Join Nuevocor for an educational webinar on LMNA-related dilated cardiomyopathy (LMNA-related DCM), one of the most serious genetic forms of heart muscle disease. Learn about the disease, current treatment challenges, and innovative research that may help shape the future of care.
Nuevocor’s lead investigational therapy, NVC-001, is a one-time gene therapy designed to target the underlying disease mechanism of LMNA-related DCM rather than simply treating its symptoms. Currently there are no approved disease-specific therapies for LMNA-related DCM – and for a community awaiting new therapies – NVC-001 represents an important area of research.
The SUNBEAM-LMNA clinical trial is the first study evaluating NVC-001 in humans and is now enrolling participants at sites across the United States. The trial is evaluating the safety and preliminary clinical effects of NVC-001.
During this webinar, we will discuss:
- What LMNA-related DCM is and how it affects patients and families
- How the NVC-001 gene therapy works
- An overview of the SUNBEAM-LMNA clinical trial
- Who may be eligible to participate
- Important medical and safety considerations for patients considering a gene therapy clinical trial
- You’ll also hear from the physicians and scientists as they discuss the science behind NVC-001, the rationale for the clinical trial, and the goals of the SUNBEAM-LMNA study.
Presenters
Monica Shah, MD, FACC
Chief Medical Officer, Nuevocor
Dr. Shah is a board-certified heart failure and transplant cardiologist with more than two decades of experience in cardiovascular medicine, clinical research, gene therapy, and drug development. As Chief Medical Officer of Nuevocor, she leads the global clinical development of NVC-001. Prior to joining Nuevocor, Dr. Shah served as Chief Medical Officer at CTI Clinical Trial & Consulting, Senior Vice President and Global Program Head for AAV Gene Therapy at Rocket Pharmaceuticals, and Global Head of Cell and Gene Therapy at IQVIA. Earlier in her career, she spent nearly a decade at the National Heart, Lung, and Blood Institute at the National Institutes of Health, where she served as Deputy Chief of the Heart Failure and Arrhythmias Branch. She has held academic faculty appointments at several leading medical institutions. Dr. Shah currently serves as President of the Greater Washington Region Board of Directors of the American Heart Association.
John Giudicessi, MD, PhD
Cardiologist and Physician-Scientist, Mayo Clinic
Dr. Giudicessi is a cardiologist and physician-scientist at Mayo Clinic whose clinical practice and research focus on inherited cardiovascular diseases, including LMNA cardiomyopathy. His research has advanced the understanding of how LMNA genetic variants influence disease progression, arrhythmia risk, and clinical outcomes. He has authored numerous peer-reviewed publications spanning cardiovascular genetics, precision medicine, and inherited arrhythmia syndromes, and is actively involved in developing innovative approaches to the diagnosis and treatment of genetic heart disease. Dr. Giudicessi completed his medical, doctoral, and cardiology training at Mayo Clinic, where he continues to care for patients and lead translational research.
Register Now